New NSAID aims to match existing drug for back pain relief
NCT ID NCT06595004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 study tested a new drug called HCP1004 against an existing painkiller (RLD2401) in 310 adults with chronic low-back pain lasting at least 3 months. The goal was to see if HCP1004 works just as well for pain and function, while monitoring safety. Participants took the drugs daily for at least 12 weeks, and researchers measured pain levels using a standard scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HCP1004 (a nonsteroidal anti-inflammatory drug, NSAID)
What this could lead to
If successful, this could offer a new NSAID option for managing chronic low-back pain with similar effectiveness to existing drugs.
What could go wrong
This is a non-inferiority trial, meaning it aims to show HCP1004 is not worse than the reference drug, not that it is better. Results may not show a meaningful advantage, and NSAIDs carry risks like stomach ulcers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LOW-BACK PAIN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanyang University Seoul Hospital
Seoul, Seoul, 04763, South Korea